Corrigendum on a Novel Cancer Drug Trial: The Importance of Accurate Data Presentation
A corrigendum has been published for an interim analysis of a first-in-human phase I/Ib study of HRO761, an oral Werner (WRN) helicase inhibitor, in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors. The original publication contained an incorrectly formatted data table, which has now been rectified. This study represents a significant step in targeted oncology, investigating a new class of therapeutic agent for cancers with specific genetic profiles.
Why it might matter to you: For professionals in laboratory medicine, this highlights the critical role of accurate data presentation in clinical research, especially for novel molecular diagnostics and companion diagnostics. The study’s focus on MSI-H/dMMR tumors underscores the ongoing integration of complex molecular testing, like next-generation sequencing (NGS), into therapeutic decision-making. Ensuring flawless data reporting in such trials is paramount for validating new biomarkers and guiding future diagnostic and monitoring protocols.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
